SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged violations of federal securities laws related to misleading statements about its drug ELEVIDYS [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Sarepta securities between June 22, 2022, and June 24, 2025, inclusive [2]. - The complaint alleges that Sarepta's executives made false or misleading statements regarding the safety and trial protocols of ELEVIDYS, which posed significant risks to patients and could lead to regulatory scrutiny [3]. Group 2: Impact on Stock - Following the disclosure of a death related to ELEVIDYS treatment on March 18, 2025, Sarepta's stock price fell by $27.81, or 27.44%, closing at $73.54 [4]. Group 3: Next Steps for Investors - Investors who suffered losses in Sarepta have until August 25, 2025, to request to be appointed as lead plaintiff in the class action [5]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [6]. Group 4: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm that has recovered hundreds of millions of dollars for investors in securities fraud class actions [7].